- Home
- SPT vs IMNM Comparison
SPT vs IMNM Comparison
Compare SPT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- IMNM
- Stock Information
- Founded
- SPT 2010
- IMNM 2006
- Country
- SPT United States
- IMNM United States
- Employees
- SPT N/A
- IMNM N/A
- Industry
- SPT Computer Software: Prepackaged Software
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- SPT Technology
- IMNM Health Care
- Exchange
- SPT Nasdaq
- IMNM Nasdaq
- Market Cap
- SPT 1.1B
- IMNM 945.8M
- IPO Year
- SPT 2019
- IMNM 2020
- Fundamental
- Price
- SPT $16.23
- IMNM $10.85
- Analyst Decision
- SPT Buy
- IMNM Strong Buy
- Analyst Count
- SPT 11
- IMNM 5
- Target Price
- SPT $29.64
- IMNM $26.40
- AVG Volume (30 Days)
- SPT 602.5K
- IMNM 849.3K
- Earning Date
- SPT 08-06-2025
- IMNM 08-19-2025
- Dividend Yield
- SPT N/A
- IMNM N/A
- EPS Growth
- SPT N/A
- IMNM N/A
- EPS
- SPT N/A
- IMNM N/A
- Revenue
- SPT $418,413,000.00
- IMNM $10,938,000.00
- Revenue This Year
- SPT $12.33
- IMNM N/A
- Revenue Next Year
- SPT $11.83
- IMNM $259.34
- P/E Ratio
- SPT N/A
- IMNM N/A
- Revenue Growth
- SPT 17.79
- IMNM N/A
- 52 Week Low
- SPT $16.18
- IMNM $5.15
- 52 Week High
- SPT $36.30
- IMNM $16.73
- Technical
- Relative Strength Index (RSI)
- SPT 26.54
- IMNM 61.15
- Support Level
- SPT $16.40
- IMNM $10.23
- Resistance Level
- SPT $19.51
- IMNM $11.08
- Average True Range (ATR)
- SPT 0.65
- IMNM 0.56
- MACD
- SPT -0.24
- IMNM -0.01
- Stochastic Oscillator
- SPT 1.50
- IMNM 59.31
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.